Amgen on Tuesday reported quarterly financial results that beat Wall Street expectations, and raised its full-year outlook, ...

The Thousand Oaks, Calif.-based biotechnology company on Tuesday reported a profit of $3.22 billion, or $5.93 a share, compared with a profit of $2.83 billion, or $5.22 a share, in the same quarter a ...

Biotech company Amgen (NASDAQ:AMGN) in Q3 CY2025, with sales up 12.4% year on year to $9.56 billion. The company’s full-year ...

Falling Fed rates and favorable policies make XLV a strong healthcare ETF pick. Read here for an analysis of its growth prospects and top holdings.

Amgen AMGN-0.60%decrease; red down pointing triangle slashed the price of its cholesterol medication by more than half for U.S. patients through a new medication-access program amid the Trump ...

Amgen has joined the wave of major drugmakers setting up direct-to-consumer programs amid President Donald Trump’s call for more DTC options to lower U.S. drug prices. The "AmgenNow" program, launched ...

Every organization and team leader wants to recruit the right talent. But what if you’re struggling to do so? Qualified applicants are few and far between, interviews aren’t yielding enough ...

We talk about silos like they’re a structural issue, but they’re actually a cultural problem. To successfully break down silos, you must use moments of change to reassess culture, aim for purposeful ...

On the heels of an FDA label expansion in August, Amgen is touting another potential avenue to extend the value of its decade-old PCSK9 cholesterol med Repatha. In the late-stage Vesalius-CV study, ...

Top-ranked Ohio State travels to Seattle this week to face unbeaten Washington. The game, with a kickoff set for 3:40 p.m. ET, will be televised by CBS. Washington is unranked but has scored an ...

Clear visuals can make complicated ideas easier to understand, and Microsoft Visio Professional 2024 is designed to help you create them. Right now, you can get a lifetime license for Windows for ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab) to include the ...